Core Insights - QIAGEN N.V. has announced a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance forensic applications and human identification using next-generation sequencing (NGS) technologies [1][2] - The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) through advanced DNA technologies [3][6] Partnership Details - The collaboration will utilize QIAGEN's MiSeq FGx sequencing system, ForenSeq Kintelligence kits, and the ForenSeq Kintelligence HT System [1] - Snow Lab, in conjunction with Ohkomi Forensics, will establish the first indigenous-owned DNA database to identify remains of 95 African American individuals found in Sugar Land, TX [4][5] Technology and Market Potential - QIAGEN's NGS and forensic investigative genetic genealogy (FIGG) technologies can process severely degraded or contaminated DNA, which is common in forensic cases [6] - The global human identification market is projected to grow from $0.8 billion in 2024 to $1.3 billion by 2029, representing a compound annual growth rate (CAGR) of 10.7% [7] Recent Developments - In June 2024, QIAGEN launched 35 new digital PCR Microbial DNA Detection Assays for its QIAcuity platform, enhancing its microbial research capabilities [9] - QIAGEN's QIAstat-Dx Gastrointestinal Panel 2 received FDA clearance for clinical use, marking a significant advancement for the company in the U.S. market [10] Stock Performance - Over the past year, QIAGEN's shares have declined by 13.4%, compared to a 7.6% decline in the industry [11]

Missoula, Montana, and Venlo, the Netherlands, July 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics. Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System. "Our collaboration with ...

Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2492 Conference ID: 8081810 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. About QIAGEN Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Access the audio webcast - Click here: Access Webcast ...

QIAGEN N.V. (QGEN) recently lauded the new guidelines in the United States that recommend screening atrisk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QuantiFERON-TB Gold Plus (QFT-Plus). The latest guidelines from the American Academy of Pediatrics (AAP) highlight testing for TB with modern interferon-gamma release assays (IGRAs). With this development, the company aims for its market-leading QFT-Plus to be a gold standard for blood-based tuberculosis d ...

Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN's market-leading QuantiFERON-TB Gold Plus (QFT-Plus). The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gam ...

The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gamma release assays (IGRAs). The new standards were published in the academy's Red Book: 2024–2027 Report of the Committee on Infectious Diseases. The AAP's recommendations follow recently updated guidelines from the American College Health Association (ACHA) stating that IGRAs are preferred over the 120-year-old tuberculin skin test (TST) for most situations relevant to college health. The upda ...

To date, QCI Interpret has analyzed and interpreted more than 4 million NGS patient test cases for oncology and hereditary diseases worldwide and processed above 850,000 clinical samples annually. It has emerged as the preferred choice for labs and organizations of all sizes globally due to its consistency, accuracy and superior content. Image Source: Zacks Investment Research NGS is changing the genomics landscape with rapid adoption and advancement within the industry. The senior vice president of QIAGEN ...

QIAGEN N.V. (QGEN) recently launched 35 new wet-lab tested dPCRs for its digital PCR (dPCR) platform QIAcuity. The new assays are available on the GeneGlobe research platform and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs). The latest development further strengthens QIAGEN's position as a leader in microbial detection and analysis. This is also likely to significantly boost its Life Sciences bu ...

Core Viewpoint - QIAGEN is committed to achieving solid profitable growth through 2028, targeting approximately 7% compound annual sales growth (CAGR) at constant exchange rates and aiming for at least a 31% adjusted operating income margin by 2028 [1][4][13]. Group 1: Financial Targets and Growth Strategy - QIAGEN plans to return at least $1 billion to shareholders from 2024 to 2028, excluding value-creating M&A opportunities [4][16]. - The company aims for at least $2 billion in combined annual sales from its growth pillars by 2028, supported by new product launches and significant investments [7]. - QIAGEN has a goal to achieve at least a 31% adjusted operating income margin by 2028, driven by efficiency initiatives and digitization [13][14]. Group 2: Product Development and Innovation - QIAGEN is focusing on the QIAcuity digital PCR system, planning to triple the number of sales specialists and launch over 100 new assays, with regulatory clearance for clinical use expected in 2024 [7]. - The company confirmed plans for new panels for syndromic diagnosis, including submissions for meningitis and other conditions by 2028 [8]. - QIAGEN Digital Insights will see at least nine new product launches by 2028, with a 40% expansion in the commercial team [9][10]. Group 3: Operational Efficiency and Digitization - QIAGEN is implementing initiatives to streamline its portfolio and improve operational margins, including the discontinuation of the NeuMoDx system [14]. - The company is pursuing about 30 AI initiatives to enhance growth and profitability [14]. - Plans include upgrading the SAP enterprise resource system to simplify organizational processes [14]. Group 4: Leadership and Corporate Responsibility - QIAGEN emphasizes the importance of a strong culture among its 6,000 employees, focusing on empowerment and accountability to achieve its 2028 targets [17]. - The company reaffirms its commitment to ESG goals, including a target to reach net zero carbon emissions by 2050 [17].

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest version of QCI Interpret introduces ...